Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors

Oncologist

Volumn 15, Issue 12, 2010, Pages 1270-1272

  Bighin, Claudia ^a   Lunardi, Gianluigi ^a,b   del Mastro, Lucia ^a   Marroni, Paola ^a   Taveggia, Paola ^a   Levaggi, Alessia ^a   Giraudi, Sara ^a   Pronzato, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Aromatase inhibitors; Estrone sulphate; Follicle stimulating hormone; Male breast cancer; Testosterone

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTRONE SULFATE; FOLLITROPIN; LETROZOLE; NAVELBINE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TESTOSTERONE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTRONE BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LUNG DISEASE; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; TESTOSTERONE BLOOD LEVEL;

AROMATASE INHIBITORS; BREAST NEOPLASMS, MALE; ESTRONE; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 78650993936     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0102     Document Type: Article

References (13)

1. Turner KJ, Morley M, Atanassova N et al. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 2000;164:225-238.
2. Mauras N, O'Brien KO, Klein KO et al. Estrogen suppression in males: Metabolic effects. J Clin Endocrinol Metab 2000;85:2370-2377.
3. Doyen J, Italiano A, Largillier R et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 2010;21: 1243-1245.
4. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24:e42-e43.
5. Brind JL, Chervinsky K, Völgelman JH et al. Radioimmunoassay of estrone sulfate in the serum of normal men after a non-chromatographic procedure that eliminates interference from dehydroepiandrosterone sulfate. Steroids 1990;55:32-35.
6. Lønning PE, Johannessen DC, Thorsen T. Alteration in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989;60:107-111.
7. Gray A, Feldman HA, McKinlay JB et al. Age, disease, and changing sex hormone levels in middle aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-1025.
8. Franz C, Watson D, Longcope C. Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids 1979;34:563-573.
9. Loriaux DL, Ruder HJ, Lipsett MB. The measurement of estrone sulfate in plasma. Steroids 1971;18:463-472.
10. Nahleh ZA. Hormonal therapy for male breast cancer: A different approach for a different disease. Cancer Treat Rev 2006;32:101-105.
11. Kaisary AL, Tyrrell CJ, Peeling WB et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-508.
12. Daniell HW, Dunn SR, Ferguson DW et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186.
13. G. Lunardi, L. Del Mastro, M. Serra et al. Plasma levels of estrone sulphate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: Association with single nucleotide polymorphisms (SNPs) of CYP19A1. J Clin Oncol 2009;27(15 suppl):555.